November 2025 therapeutic delivery: industry update
Abstract
November 2025 saw the approval of a number of products which employ a variety of delivery technologies including Johnson and Johnson's DARZALEX FASPRO (with Haloyzyme's ENHAZE), Merck's KEYTRUDA QLEX, and Regeneron's EYLEA HD. It was also a busy month for acquisitions with Halozyme completing the acquisition of Elektrofi which gives it access to the microparticulate technology Hypercon. Halozyme also announced a collaboration with the Dutch company Merus, for the development of a subcutaneous formulation of petosemtamab. Positive clinical trial data was announced for a number of companies including EyePoint, Tiziana, Nasus, and Tonix.
Fields of Study & Subjects
Advanced Drug Delivery Systems
Monoclonal and Polyclonal Antibodies Research
Pharmaceutical Economics and Policy
Publication details
- Journal / source
- Therapeutic Delivery
- Volume
- 17
- Issue
- 2
- Pages
- 91–97
- Publication date
- 30 January 2026
- Language
- EN